Peter Blume-Jensen - 14 Nov 2024 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role: President and CEO, Director
Signature: /s/ Rasmus Holm-Jorgensen, Attorney-in-Fact for Peter Blume-Jensen
Issuer symbol: ACRV
Transactions as of: 14 Nov 2024
Net transactions value: -$477,228
Form type: 4
Filing time: 18 Nov 2024, 16:26:54 UTC
Previous filing: 23 Aug 2024
Next filing: 25 Nov 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRV	Common Stock	Tax liability	$473,347	-59,766	-2.5%	$7.92	2,362,747	14 Nov 2024	Direct	F1, F2
transaction	ACRV	Common Stock	Tax liability	$3,881	-490	-0.15%	$7.92	316,756	14 Nov 2024	See Footnote	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
F2	These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
F3	These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.